ABSTRACT
A 65-year-old man experiencing chest oppression was admitted to our hospital. Contrast-enhanced chest computed tomography (CT) showed a 71×52-mm cystic mass with an enhanced wall in the thymus. The CT-guided needle biopsy of the tumor only revealed the presence of necrotic tissue. However, the tumor spontaneously decreased in size significantly to 33×21 mm in 2 months. The patient underwent right hemi-lobectomy of the thymus, which showed necrotic tissue in the center of the mass;the fibrotic cystic wall included several masses of type B3 thymoma cells( so called" well-differentiated thymic carcinoma", Masaoka stage II). Because of avoiding local recurrence, extended thymectomy including lymph node resection was additionally performed. The patient received radiation therapy postoperatively and has shown no sign of recurrence in 3 years of follow-up care.
Subject(s)
Neoplasm Regression, Spontaneous , Thymoma/surgery , Thymus Neoplasms/surgery , Aged , Humans , Male , Postoperative Period , Thymoma/diagnostic imaging , Thymus Neoplasms/diagnostic imaging , Thymus Neoplasms/pathology , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
The patient was a 45-year-old woman who had ascending colon cancer with multiple paramesenteric and paraaortic lymph node metastases. Combined l-LV 400 mg/body (250 mg/m2) +5-FU 950 mg/body (600 mg/m2) therapy was carried out as neoadjuvant chemotherapy. After 2 cycles of this therapy, the lymph node metastases were not detectable on computed tomography. Thus, right hemicolectomy was performed (D3, CurB). It is suggested that l-LV+5-FU therapy may be useful for advanced colon cancer as neoadjuvant chemotherapy.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colonic Neoplasms/drug therapy , Adenocarcinoma/secondary , Adenocarcinoma/surgery , Chemotherapy, Adjuvant , Colectomy , Colonic Neoplasms/pathology , Colonic Neoplasms/surgery , Drug Administration Schedule , Female , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Lymphatic Metastasis , Middle Aged , Preoperative CareABSTRACT
Case 1: A 77-year-old woman with advanced gastric cancer and peritoneal dissemination was treated with TS-1/CDDP therapy. TS-1 (100 mg/day) was orally administered for 21 days and CDDP (70 mg/body) was administered intravenously on day 8. After 2 courses reduction in size of the primary carcinoma was observed (PR). The duration of the PR and the survival time were over 1 year and 6 months. Case 2: A 77-year-old woman with recurrent abdominal and liver metastasis from advanced gastric cancer was treated with TS-1/CDDP therapy. TS-1 (100 mg/day) was orally administered for 21 days and CDDP (80 mg/body) was administered intravenously on day 8. The reduction was judged to be CR for the liver metastasis and PR for the abdominal tumor (total judgment: PR). The duration of the PR and the survival time were over 1 year and 5 months. It is suggested that TS-1/CDDP chemotherapy is useful for advanced and recurrent gastric cancer.
